Overview

InCytu Incorporated is developing a family of intelligent biopolymer devices that accelerate healing, enhance tissue regeneration or focus the immune system to destroy cancer.  Called Cellarium^™, these in situ bioactive devices (iBDs) are made from existing, clinically understood materials and bio-molecules,  and are protected by a broad, Harvard-developed (Prof. David Mooney et al), intellectual property portfolio.

Cellarium™ bioactive, polymer-based scaffold allows the simultaneous in-vivo control of the following:

• Selective attraction of cell populations from the patient,
• Retention and proliferation of those cells,
• Education, maturation and/or differentiation of those cells,
• Spatiotemporal export of the cells to integrate naturally,
• Local release of factors to optimize integration,
• Resorption of the Cellarium to stop therapy and remove any foreign material

Appropriate combinations of scaffold composition, architecture, growth factors, proteins, and adhesion molecules can be used to obtain complex control over a variety of cell and tissue types. This adaptability enables a broad range of applications to address patient needs for an array of underserved market opportunities.  In addition, for applications where existing biology is insufficient, the Cellarium can be preloaded with cells.